Cost-effectiveness and budget impact of saxagliptine as additional therapy to metformin for the treatment of diabetes mellitus type 2 in the Brazilian private health system

Nita ME, Eliaschewitz FG, Ribeiro E, Asano E, Barbosa E, Takemoto M, Donato B, Rached R, Rahal E

Record Status
This is an economic evaluation that meets the criteria for inclusion on NHS EED.

Bibliographic details

Indexing Status
Subject indexing assigned by NLM

MeSH
Adamantane /administration & dosage /analogs & derivatives /economics; Cost-Benefit Analysis; Diabetes Mellitus, Type 2 /drug therapy /economics; Dipeptides /administration & dosage /economics; Drug Therapy, Combination /economics; Female; Humans; Hypoglycemic Agents /administration & dosage /economics; Male; Metformin /administration & dosage /economics; Middle Aged; Private Sector; Thiazolidinediones /administration & dosage /economics

AccessionNumber
22013015305

Date bibliographic record published
25/04/2013